BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Treatment
64 results:

  • 1. Select ezh2 inhibitors enhance viral mimicry effects of DNMT inhibition through a mechanism involving NFAT:AP-1 signaling.
    Chomiak AA; Tiedemann RL; Liu Y; Kong X; Cui Y; Wiseman AK; Thurlow KE; Cornett EM; Topper MJ; Baylin SB; Rothbart SB
    Sci Adv; 2024 Mar; 10(13):eadk4423. PubMed ID: 38536911
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. ezh2 as a potential therapeutic target for gastrointestinal cancers.
    Hashemi M; Nazdari N; Gholamiyan G; Paskeh MDA; Jafari AM; Nemati F; Khodaei E; Abyari G; Behdadfar N; Raei B; Raesi R; Nabavi N; Hu P; Rashidi M; Taheriazam A; Entezari M
    Pathol Res Pract; 2024 Jan; 253():154988. PubMed ID: 38118215
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Impact of curcumin on ferroptosis-related genes in colorectal cancer: Insights from in-silico and in-vitro studies.
    Firouzjaei AA; Aghaee-Bakhtiari SH; Tafti A; Sharifi K; Abadi MHJN; Rezaei S; Mohammadi-Yeganeh S
    Cell Biochem Funct; 2023 Dec; 41(8):1488-1502. PubMed ID: 38014635
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions.
    Zhang J; Li C; Sun L; Sun D; Zhao T
    Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37921068
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Phosphorylation of ezh2 differs HER2-positive breast cancer invasiveness in a site-specific manner.
    Yu F; Li L; Zhang M; Sun S
    BMC Cancer; 2023 Oct; 23(1):948. PubMed ID: 37803297
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Network pharmacology-based anti-colorectal cancer activity of piperlonguminine in the ethanolic root extract of Piper longum L.
    Singh I; Das R; Kumar A
    Med Oncol; 2023 Oct; 40(11):320. PubMed ID: 37796360
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Combined inhibition of ezh2 and the autotaxin-LPA-LPA2 axis exerts synergistic antitumor effects on colon cancer cells.
    Long Y; Wang Y; Qu M; Zhang D; Zhang X; Zhang J
    Cancer Lett; 2023 Jul; 566():216226. PubMed ID: 37230222
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
    Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
    Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. BET Inhibitors Induce p53-Independent Growth Arrest in HCT116 Cells via Epigenetic Control of the E2F1/c-MYC Axis.
    Jeon D; Kim N; Um SJ
    Biol Pharm Bull; 2023; 46(1):12-18. PubMed ID: 36596519
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. MYC-Induced Upregulation of Lncrna ELFN1-AS1 Contributes to Tumor Growth in colorectal cancer via Epigenetically Silencing TPM1.
    Li C; Hong S; Hu H; Liu T; Yan G; Sun D
    Mol Cancer Res; 2022 Nov; 20(11):1697-1708. PubMed ID: 35857351
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Activation of FXR and inhibition of ezh2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression.
    Yu J; Yang K; Zheng J; Zhao P; Xia J; Sun X; Zhao W
    Cell Death Dis; 2022 Apr; 13(4):388. PubMed ID: 35449124
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. ezh2 Inhibitors Suppress colorectal cancer by Regulating Macrophage Polarization in the Tumor Microenvironment.
    Li C; Song J; Guo Z; Gong Y; Zhang T; Huang J; Cheng R; Yu X; Li Y; Chen L; Ma X; Sun Y; Wang Y; Xue L
    Front Immunol; 2022; 13():857808. PubMed ID: 35432300
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Downregulation of MEIS1 mediated by ELFN1-AS1/ezh2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer.
    Li Y; Gan Y; Liu J; Li J; Zhou Z; Tian R; Sun R; Liu J; Xiao Q; Li Y; Lu P; Peng Y; Peng Y; Shu G; Yin G
    Signal Transduct Target Ther; 2022 Mar; 7(1):87. PubMed ID: 35351858
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. [Relationship between Expression of Runt-related Transcription Factor 3 and Enhancer of zeste Homolog 2 Proteins and Sensitivity to Neoadjuvant Chemotherapy in Locally Advanced Rectal cancer].
    Yuan ZL; Wu XL; Qu M; Xue J; Han L; Sun GY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Dec; 43(6):856-864. PubMed ID: 34980322
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Tumor-suppressive function of ezh2 is through inhibiting glutaminase.
    Liu Y; Tu CE; Guo X; Wu C; Gu C; Lai Q; Fang Y; Huang J; Wang Z; Li A; Liu S
    Cell Death Dis; 2021 Oct; 12(11):975. PubMed ID: 34671029
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A Multidisciplinary Approach to Rectal cancer treatment in Ulcerative Colitis Results in High Rate of Restorative Minimally Invasive Surgery.
    Carvello M; Bellato V; Maroli A; Hart A; Danese S; Warusavitarne J; Spinelli A
    J Crohns Colitis; 2022 Feb; 16(2):244-250. PubMed ID: 34346483
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Hospital variation and outcomes of simultaneous resection of primary colorectal tumour and liver metastases: a population-based study.
    Krul MF; Elfrink AKE; Buis CI; Swijnenburg RJ; Te Riele WW; Verhoef C; Gobardhan PD; Dulk MD; Liem MSL; Tanis PJ; Mieog JSD; van den Boezem PB; Leclercq WKG; Nieuwenhuijs VB; Gerhards MF; Klaase JM; Grünhagen DJ; Kok NFM; Kuhlmann KFD; ;
    HPB (Oxford); 2022 Feb; 24(2):255-266. PubMed ID: 34305003
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. MicroRNA-506-3p inhibits colorectal cancer cell proliferation through targeting enhancer of zeste homologue 2.
    Ai L; Luo X; Yan X; Jiang S
    Bioengineered; 2021 Dec; 12(1):4044-4053. PubMed ID: 34288823
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. A KLF4/PiHL/ezh2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer.
    Deng X; Kong F; Li S; Jiang H; Dong L; Xu X; Zhang X; Yuan H; Xu Y; Chu Y; Peng H; Guan M
    Cell Death Dis; 2021 May; 12(5):485. PubMed ID: 33986248
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting ezh2 stability.
    Zhou S; Peng J; Xiao L; Zhou C; Fang Y; Ou Q; Qin J; Liu M; Pan Z; Hou Z
    Cell Death Dis; 2021 May; 12(5):463. PubMed ID: 33966039
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.